The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE

Autoimmunity Reviews

Volumn 11, Issue 5, 2012, Pages 373-

  Wang, Chao ^a   Pan, Hai Feng ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoreactive B lymphocytes; CD19; Rituximab; SLE

Indexed keywords

CD19 ANTIGEN; CYCLOPHOSPHAMIDE; RITUXIMAB;

ANTIGEN BINDING; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOREACTIVE B LYMPHOCYTE; B LYMPHOCYTE; BLOOD; CELL EXPANSION; CELL GROWTH; CELL MATURATION; CELL SURVIVAL; DRUG EFFICACY; DRUG TARGETING; GENE SILENCING; HUMAN; LETTER; LONG TERM CARE; PATHOPHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES;

EID: 84863132224     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.01.002     Document Type: Letter

References (5)

1. Nikolova K.A., Mihaylova N.M., Voynova E.N., Tchorbanov A.I., Voll R.E., Vassilev T.L. Selective silencing of autoreactive B lymphocytes-following the Nature's way. Autoimmun Rev 2010, 9:775-779.
2. Bacconnier L., Combe B., Canaud B., Morel J. Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19. Rheumatology (Oxford) 2010, 49:2452-2453.
3. Levesque M.C. Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 2009, 157:198-208.
4. Sfikakis P.P., Karali V., Lilakos K., Georgiou G., Panayiotidis P. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion. Clin Immunol 2009, 132:19-31.
5. Mok M.Y. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010, 13:3-11.